Abbott Laboratories $ABT Shares Sold by Aaron Wealth Advisors LLC

Aaron Wealth Advisors LLC reduced its position in Abbott Laboratories (NYSE:ABT) by 53.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,746 shares of the healthcare product maker’s stock after selling 15,701 shares during the quarter. Aaron Wealth Advisors LLC’s holdings in Abbott Laboratories were worth $1,411,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. American National Bank of Texas raised its stake in Abbott Laboratories by 2.4% during the 4th quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker’s stock valued at $427,000 after acquiring an additional 79 shares during the last quarter. Nia Impact Advisors LLC grew its stake in shares of Abbott Laboratories by 2.2% in the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock valued at $504,000 after purchasing an additional 79 shares during the last quarter. Park Place Capital Corp increased its holdings in shares of Abbott Laboratories by 11.0% in the fourth quarter. Park Place Capital Corp now owns 815 shares of the healthcare product maker’s stock valued at $102,000 after purchasing an additional 81 shares during the period. Lantern Wealth Advisors LLC raised its stake in shares of Abbott Laboratories by 1.7% during the third quarter. Lantern Wealth Advisors LLC now owns 5,028 shares of the healthcare product maker’s stock worth $674,000 after purchasing an additional 84 shares during the last quarter. Finally, Clayton Financial Group LLC lifted its holdings in shares of Abbott Laboratories by 1.4% during the fourth quarter. Clayton Financial Group LLC now owns 6,217 shares of the healthcare product maker’s stock worth $779,000 after purchasing an additional 84 shares during the period. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling at Abbott Laboratories

In other news, Director Daniel J. Starks purchased 10,000 shares of the business’s stock in a transaction dated Monday, April 27th. The shares were acquired at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the purchase, the director directly owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. The trade was a 0.15% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Philip P. Boudreau purchased 2,200 shares of Abbott Laboratories stock in a transaction dated Thursday, April 23rd. The stock was bought at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the transaction, the chief financial officer directly owned 2,200 shares in the company, valued at $201,300. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 0.46% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on ABT. Daiwa Securities Group cut shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price objective on the stock. in a research note on Wednesday, April 22nd. Citigroup lowered their target price on shares of Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Benchmark dropped their price target on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Weiss Ratings cut shares of Abbott Laboratories from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, June 16th. Finally, Leerink Partners lowered their target price on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research report on Tuesday, April 21st. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $118.30.

Abbott Laboratories Trading Up 0.8%

NYSE:ABT opened at $94.02 on Friday. The stock has a market cap of $163.77 billion, a price-to-earnings ratio of 26.34, a PEG ratio of 1.61 and a beta of 0.63. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49. The business has a fifty day moving average of $89.08 and a 200-day moving average of $105.38.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same period in the prior year, the business posted $1.09 earnings per share. Abbott Laboratories’s revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.7%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s payout ratio is currently 70.59%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.